Good point, Elleburra. The corollary is that, while it was a not...

Good point, Elleburra. The corollary is that, while it was a not inconsiderable parcel, it was also far too small to be anybody close to the company walking, if they had gleaned some inkling that the quarterly might be worse than we expect. All the indications - hints at the AGM, US newspaper references, reports of takeup by pathology labs - have been positive in the recent past. I am looking for a revenue figure well in excess of $4.5m, possibly closer to $5m, which would probably be viewed very favourably by the market.

Cheers, Prime